Thomson Reuters Foundation

Inform - Connect - Empower

Pfizer to pay ${esc.dollar}55 million to settle Protonix case

Source: Thomson Reuters Foundation - Wed, 12 Dec 2012 16:56 GMT
Author: Reuters
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

Dec 12 (Reuters) - Pfizer Inc will pay ${esc.dollar}55 million plus interest to settle charges that Wyeth promoted its acid reflux drug Protonix for unapproved uses and made unproven claims about the medicine, the U.S. Department of Justice said on Wednesday.

The infractions took place between February 2000 and June 2001, long before the world's largest drugmaker acquired Wyeth in 2009 for ${esc.dollar}68 billion. Protonix, which belongs to a class of widely used medicines called proton pump inhibitors (PPI), has since gone off patent and is available in cheap generic versions as pantoprazole.

Protonix was approved by the U.S. Food and Drug Administration for short-term treatment of erosive esophagitis -a condition related to gastro-esophageal reflux disease, or GERD, that can only be diagnosed via endoscopy.

The Justice Department accused Wyeth of training its sales force to promote Protonix for all forms of GERD, which is far more common and likely to lead to significantly higher sales.

In addition, Wyeth allegedly promoted Protonix as the "best PPI for nighttime heartburn" even though there was never any clinical evidence that it was more effective than any other PPI, such as AstraZeneca's Nexium, for that use, the Justice Dept said.

"Wyeth tried to cheat the system by obtaining a limited FDA approval for Protonix, fully intending to promote this drug for additional, unapproved uses," U.S. Attorney Carmen Ortiz said in a statement.

Pfizer shares were down 10 cents at ${esc.dollar}25.54 in midday trading on the New York Stock Exchange.

(Reporting by Bill Berkrot; Editing by Maureen Bavdek)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular

Latest slideshow

See allSee all
Featured jobs